Clinical Trials
20 trialsNCT07468916 2026-05-06
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT03862157 2026-03-11
Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04942080 2026-03-06
CALRSUIVI
University Hospital, Angers
Phase NA Recruiting
NCT07203768 2025-12-26
ET2PV
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Recruiting
NCT04576156 2025-12-04
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
Phase 3 Active not recruiting
NCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT05482971 2025-08-13
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
PharmaEssentia
Phase 2 Active not recruiting
NCT05423691 2025-04-13
TREG108
Cellenkos, Inc.
Phase 1 Recruiting
NCT05005182 2024-09-19
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Mayo Clinic
Phase 2 Terminated
NCT04637009 2024-08-02
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT06246006 2024-02-07
MPL - NPM
Centre Hospitalier Universitaire de Nīmes
Unknown
NCT03717519 2023-07-20
PLTCRC
Azienda Ospedaliera Universitaria Integrata Verona
Completed
NCT04354727 2022-07-12
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Ascentage Pharma Group Inc.
Phase 1/2 Withdrawn
NCT01998828 2020-04-20
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT01787552 2020-04-15
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Novartis
Phase 1/2 Completed
NCT00946270 2019-06-10
Pomalidomide for Myelofibrosis Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00509899 2018-03-12
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Incyte Corporation
Phase 1/2 Completed
NCT02125318 2017-02-27
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Galena Biopharma, Inc.
Phase 2 Completed
NCT02805868 2016-10-24
Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
Northwestern University
Phase EARLY_PHASE1 Withdrawn